Emergent BioSolutions Inc. — Form 8-K Summary
Report date: October 16, 2026. The filing reports a planned chief financial officer transition; it does not provide quarterly or annual financial results.
Business context and reporting period
Emergent BioSolutions Inc. (NYSE: EBS) is a Delaware corporation headquartered in Gaithersburg, Maryland. The 8-K reports an officer change, not a financial reporting-period update.
Financial metrics and material period changes
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating-performance figures. It contains no comparable-period financial results.
Compensation details disclosed: Interim CFO Frank Vargo’s current base salary is $328,000. Beginning January 1, 2027, he will receive an additional $3,850 per pay period during the interim appointment. His salary, bonus, and equity awards will otherwise remain commensurate with his prior seniority and position and be reviewed on the cycle applicable to other executives. Richard Lindahl’s advisor compensation will be materially consistent with his current compensation; the filing does not state an amount.
Leadership transition and outlook
- CFO Richard Lindahl will step down as principal financial and accounting officer effective December 31, 2026, continue as an advisor, and retire March 31, 2027.
- Frank Vargo, currently Vice President and Treasurer, will become Interim CFO and principal financial and accounting officer on January 1, 2027.
- Lindahl is expected to assist with the transition, including preparation and filing of the company’s Form 10-K for the year ending December 31, 2026.
- The filing gives no permanent CFO appointment timetable, financial guidance, or discussion of financial risks or contingencies. It references an October 16 press release, but its contents are not included in the supplied filing text.
Important facts for investors to verify
- Whether the CFO transition and 2026 Form 10-K preparation proceed on the stated schedule.
- Whether the company appoints a permanent CFO and whether the interim compensation terms change.
- The referenced press release and subsequent company disclosures for additional transition details.